David Wallace1, Douglas R Taylor2, Haitao Pan3, Scott Hwang4, John T Lucas5, Paul Klimo2,6, Santhosh A Upadhyaya7, Frederick A Boop2,6. 1. College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 2. Department of Neurosurgery, LeBonheur Children's Hospital, Memphis, Tennessee. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee. 7. Division of Neuro-Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Abstract
BACKGROUND: Despite improved survival, many pediatric brain tumor survivors receiving radiation therapy (RT) experience late effects. PROCEDURE: To study calvarial lesions in this population, we retrospectively reviewed records of patients undergoing neurosurgical evaluation for calvarial bone lesions detected in posttreatment follow-up imaging at St. Jude Children's Research Hospital. Primary tumor diagnosis, treatment, imaging, surgical intervention, and histopathology from patients with radiographic evidence of lesions followed for ≥2 years post-RT were studied. RESULTS: For 17 patients with 18 index lesions, median time to lesion manifestation was 2.34 years. Medulloblastoma patients developed lesions at a shorter interval from RT than ependymoma patients (P = .05). Twelve of 14 lesions requiring surgery were benign fibro-osseous or sclerotic. Two malignant lesions distinct from the primary tumor had genetic predisposition to malignancy. CONCLUSION: Most calvarial lesions arising post-RT are benign and fibro-osseous. Serial imaging is recommended, and high index of suspicion for malignant lesions is warranted for patients genetically predisposed to cancer.
BACKGROUND: Despite improved survival, many pediatric brain tumor survivors receiving radiation therapy (RT) experience late effects. PROCEDURE: To study calvarial lesions in this population, we retrospectively reviewed records of patients undergoing neurosurgical evaluation for calvarial bone lesions detected in posttreatment follow-up imaging at St. Jude Children's Research Hospital. Primary tumor diagnosis, treatment, imaging, surgical intervention, and histopathology from patients with radiographic evidence of lesions followed for ≥2 years post-RT were studied. RESULTS: For 17 patients with 18 index lesions, median time to lesion manifestation was 2.34 years. Medulloblastoma patients developed lesions at a shorter interval from RT than ependymoma patients (P = .05). Twelve of 14 lesions requiring surgery were benign fibro-osseous or sclerotic. Two malignant lesions distinct from the primary tumor had genetic predisposition to malignancy. CONCLUSION: Most calvarial lesions arising post-RT are benign and fibro-osseous. Serial imaging is recommended, and high index of suspicion for malignant lesions is warranted for patients genetically predisposed to cancer.
Authors: Karen Tsui; Amar Gajjar; Chenghong Li; Deokumar Srivastava; Alberto Broniscer; Cynthia Wetmore; Larry E Kun; Thomas E Merchant; David W Ellison; Brent A Orr; Frederick A Boop; Paul Klimo; Jordan Ross; Leslie L Robison; Gregory T Armstrong Journal: Neuro Oncol Date: 2014-11-13 Impact factor: 12.300
Authors: Roger J Packer; Amar Gajjar; Gilbert Vezina; Lucy Rorke-Adams; Peter C Burger; Patricia L Robertson; Lisa Bayer; Deborah LaFond; Bernadine R Donahue; MaryAnne H Marymont; Karin Muraszko; James Langston; Richard Sposto Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544
Authors: Tara M Brinkman; Kirsten K Ness; Zhenghong Li; I-Chan Huang; Kevin R Krull; Amar Gajjar; Thomas E Merchant; James L Klosky; Robyn E Partin; Ingrid Tonning Olsson; Frederick Boop; Paul Klimo; Wassim Chemaitilly; Raja B Khan; Deokumar Srivastava; Leslie L Robison; Melissa M Hudson; Gregory T Armstrong Journal: J Clin Oncol Date: 2018-08-09 Impact factor: 44.544
Authors: Laurie E Cohen; Joshua H Gordon; Erica Y Popovsky; Nina N Sainath; Henry A Feldman; Mark W Kieran; Catherine M Gordon Journal: Pediatr Blood Cancer Date: 2011-08-29 Impact factor: 3.167
Authors: Thomas E Merchant; Chenghong Li; Xiaoping Xiong; Larry E Kun; Frederic A Boop; Robert A Sanford Journal: Lancet Oncol Date: 2009-03 Impact factor: 41.316
Authors: James G Gurney; Nina S Kadan-Lottick; Roger J Packer; Joseph P Neglia; Charles A Sklar; Judy A Punyko; Marilyn Stovall; Yutaka Yasui; H Stacy Nicholson; Suzanne Wolden; Dawn E McNeil; Ann C Mertens; Leslie L Robison Journal: Cancer Date: 2003-02-01 Impact factor: 6.921